Selvita to provide computational chemistry services for US
Institutes for Pharmaceutical Discovery
11 April 2011
Krakow-based Selvita has signed an agreement with US drug
discovery company the Institutes for Pharmaceutical Discovery (IPD) to
provide computational chemistry services.
The aim of the agreement is to identify novel chemical compounds
that inhibit the activity of a novel protein target, proposed by
IPD. This target protein was selected as the result of a
collaboration between IPD and an academic institution, and may be
linked to an important class of human diseases.
The compounds identified during this project are expected to
demonstrate therapeutic potential as a result of their interaction
with the selected protein target. The results of the computational
analysis will be experimentally tested in drug discovery research
conducted by IPD.
The scope of the project, commissioned to Selvita, includes a
druggability study of the targeted protein, followed by a virtual
high-throughput screen of structures attainable in public databases,
and the interpretation of the “lead-likeness” of the proposed
“We expect to identify a set of chemical structures possessing
the desired characteristics of specific functional inhibitors, with
potential therapeutic activity. We are very pleased to be working
with Selvita on this novel target,” said Paul Beckett, Senior
Director, Synthetic Medicinal Chemistry, at IPD.
"We are very pleased that we can cooperate with The Institutes
for Pharmaceutical Discovery,” said Piotr Prelich, Selvita’s VP of
Sales and Marketing. “This project is a great chance for Selvita to
show the potential of our Computational Chemistry Department. We’ve
assembled an excellent team of experienced target modeling and
ligand design professionals and I’m sure we can deliver what IPD
desires. We’re looking forward to this cooperation very much.”